Qi-Ming Zhu, DO
Pulmonary Disease · Katy, TXNPI 1609019710
Payments from drug & device makers
Across 265 payments — averaging $15.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$1K
- GSK$775
- AstraZeneca$451
- Regeneron Healthcare Solutions, Inc.$398
- Amgen$327
- Inspire Medical Systems, Inc.$261
- plus $611 from 20 others
What the payments were for
- Food & beverage$3,97698%
- Education$692%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 113 | $1,222 |
| GSK | 64 | $775 |
| AstraZeneca | 12 | $451 |
| Regeneron Healthcare Solutions, Inc. | 33 | $398 |
| Amgen | 9 | $327 |
| Inspire Medical Systems, Inc. | 5 | $261 |
| AbbVie | 4 | $151 |
| Insmed, Inc. | 2 | $44 |
| Sanofi Pasteur Inc. | 2 | $41 |
| Boehringer Ingelheim | 2 | $39 |
| Phathom Pharmaceuticals, Inc. | 2 | $35 |
| Philips North America LLC | 2 | $32 |
| Amarin Pharma, Inc. | 2 | $27 |
| Edwards Lifesciences | 1 | $26 |
| Pfizer | 1 | $24 |
| Sanofi | 1 | $24 |
| Corcept Therapeutics | 1 | $22 |
| Mylan Specialty L.p. | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Pacira Pharmaceuticals Incorporated | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Lilly USA, LLC | 1 | $16 |
| Eli Lilly | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Genentech USA, Inc. | 1 | $14 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEZSPIRE$298
- FASENRA$298
- FREESTYLE LIBRE 3$134
- QULIPTA$125
- UBRELVY$125
- EVENITY$124
- Repatha$122
- Inspire Upper Airway Stimulation System$117
- BREZTRI$115
How this compares
$4,045 in reported general payments places this provider in the 55th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 608 | $511,430 |
| OfevNintedanib Esylate | 17 | $214,541 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 113 | $91,717 |
| Breo ElliptaFluticasone/Vilanterol | 72 | $56,156 |
| TezspireTezepelumab-Ekko | 12 | $54,430 |
| Spiriva RespimatTiotropium Bromide | 38 | $34,779 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 37 | $27,680 |
| Spiriva HandihalerTiotropium Bromide | 14 | $17,916 |
| SymbicortBudesonide/Formoterol Fumarate | 46 | $16,348 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 14 | $11,485 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 327 | $10,406 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 14 | $9,544 |
| Ventolin HfaAlbuterol Sulfate | 88 | $4,888 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 38 | $4,459 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 14 | $2,652 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $775 | $595,266717 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat, Stiolto Respimat | $39 | $270,34983 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Symbicort | $451 | $162,495171 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in Katy
- Charles AndrewsSan Antonio$17M
- Ivan RosasHouston$13.8M
- Shahrukh KureishyMcKinney$12.4M
- Raksha JainDallas$3.4M
- Kelly ChinDallas$2.7M
- Julie PhilleyTyler$2.4M
- Nicola HananiaHouston$2.2M
- Sandeep SahayHouston$2.1M
- Antonio AnzuetoSan Antonio$1.8M
- Diego Maselli CaceresSan Antonio$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.